Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 12/20 | 0.39 |
| ▸ | CHUK | O15111 | 12/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 2/20 | 0.31 |
| ▸ | MMP13 | P45452 | 2/20 | 0.31 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2981793 | 0.95 | KMT2A (0.38) | IKBKBCHUKBRD4KMT2A | |
| SCHEMBL2980032 | 0.93 | MMP1 (0.34) | IKBKBCHUKHPGDSMN1; SMN2MMP1 | |
| SCHEMBL2981796 | 0.90 | MMP1 (0.32) | MMP1MMP13 | |
| SCHEMBL2987895 | 0.90 | IKBKB (0.45) | IKBKBCHUKBRD4HPGDSMN1; SMN2 | |
| SCHEMBL3415805 | 0.85 | IKBKB (0.54) | IKBKBCHUKBRD4KMT2AHTR1A | |
| SCHEMBL13266036 | 0.85 | BRD4 (0.33) | IKBKBCHUKBRD4 | |
| SCHEMBL2985378 | 0.83 | IKBKB (0.56) | IKBKBCHUKBRD4KMT2AHTR1A | |
| SCHEMBL2987892 | 0.82 | IKBKB (0.38) | IKBKBCHUKHPGDSMN1; SMN2MMP1 | |
| SCHEMBL13266144 | 0.82 | KDM4E (0.31) | BRD4KMT2A | |
| SCHEMBL3415345 | 0.81 | IKBKB (0.49) | IKBKBCHUKBRD4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179139-A1 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | BAMBOROUGH PAUL | 2010-07-15 | — | — | US | disclosed |
| US-20100179139-A1 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | BAMBOROUGH PAUL | 2010-07-15 | — | — | US | disclosed |
| WO-2008145688-A2 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | GLAXO GROUP LIMITED (GB) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179139-A1 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | NFKBIA, PACSIN2, MAP3K2 | IKBKB 11/4885CHUK 22/4885BRD4 817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.